Publicaciones en colaboración con investigadores/as de University of Liverpool (17)

2023

  1. Circulating proteome for pulmonary nodule malignancy

    Journal of the National Cancer Institute, Vol. 115, Núm. 9, pp. 1060-1070

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

2022

  1. Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 65-122

2020

  1. Recent advances in alcohol-related liver disease (ALD): Summary of a Gut round table meeting

    Gut, Vol. 69, Núm. 4, pp. 764-780

2019

  1. Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

    Journal of Thoracic Oncology, Vol. 14, Núm. 3, pp. 343-357

  2. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: Results from 3 UK clinical trials

    Blood Advances, Vol. 3, Núm. 16, pp. 2474-2481

2017

  1. Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury

    Gut, Vol. 66, Núm. 6, pp. 1123-1137

2014

  1. High Mobility Group Box-1 (HMGB1) participates in the pathogenesis of Alcoholic Liver Disease (ALD)

    Journal of Biological Chemistry, Vol. 289, Núm. 33, pp. 22672-22691

2013

  1. A prognostic DNA methylation signature for stage I non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 31, Núm. 32, pp. 4140-4147

2012

  1. Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung

    Journal of Clinical Oncology, Vol. 30, Núm. 10, pp. 1129-1136

  2. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: The EUELC cohort

    European Respiratory Journal, Vol. 40, Núm. 1, pp. 177-184

  3. Progressive lung cancer determined by expression profiling and transcriptional regulation

    International Journal of Oncology, Vol. 41, Núm. 1, pp. 242-252

  4. Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development

    Lung Cancer, Vol. 75, Núm. 2, pp. 156-160

2010

  1. Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: The European Early Lung Cancer Project

    International Journal of Oncology, Vol. 37, Núm. 2, pp. 455-461

2009

  1. EUELC project: A multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration

    European Respiratory Journal, Vol. 34, Núm. 6, pp. 1477-1486

2002

  1. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations.

    International journal of oncology